Search Result

Results for "

diabetes mellitus model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Carbonic Anhydrase (1) Cholinesterase (ChE) (2) Endogenous Metabolite (1) Epigenetic Reader Domain (1) GABA Receptor (2) GLUT (1) Glycosidase (1) Isotope-Labeled Compounds (1) Potassium Channel (2) PPAR (1) Sodium Channel (2)
By Research Areas:	Cancer (1) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107482

Picamilon Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid	GABA Receptor	Neurological Disease
Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-107482A

Picamilon sodium Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate	GABA Receptor	Neurological Disease
Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-W012241

Dodecanedioic acid	Endogenous Metabolite	Metabolic Disease
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

HY-W027553

Ipidacrine NIK-247 free base	Cholinesterase (ChE) Potassium Channel Sodium Channel	Neurological Disease Metabolic Disease
Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K ⁺ and Na ⁺-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

HY-168719

PPARγ agonist 16	PPAR	Inflammation/Immunology
PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC₅₀ of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .

HY-173503

DS-1150b	GLUT	Metabolic Disease
DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .

HY-161522

α-Glucosidase-IN-63	Glycosidase Carbonic Anhydrase	Endocrinology
α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC₅₀=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of K_i= 7.0 nM. α-Glucosidase-IN-63 is orally effective. .

HY-W027553S1

Ipidacrine-d9 NIK-247-d₁₀ free base	Isotope-Labeled Compounds Cholinesterase (ChE) Potassium Channel Sodium Channel	Metabolic Disease
Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W012241

Dodecanedioic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

Cat. No.	Product Name	Chemical Structure

HY-W027553S1

Ipidacrine-d9
Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

Ipidacrine-d9

Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks